PreComb

PreComb is a Swiss-based biotechnology company that is focused on the development of proprietary technologies that enable evidence-based treatment decisions in cancer. The company's main offering is the 3DTwin® technology, a platform that uses patient-derived 3D tumor models to replicate the real cancer microenvironments. This approach is used to improve drug testing, accelerate research, and drive better clinical outcomes in precision oncology.

PreComb operates in the biotechnology and healthcare sectors, with a specific focus on oncology. Its primary clients are pharmaceutical companies, research institutions, and clinicians who are involved in the development and prescription of cancer treatments. The company collaborates with research partners by providing expert guidance in selecting and generating patient-derived 3D tumor models tailored to their studies. PreComb's business model is centered on providing its proprietary technology and expertise as a service to its partners and clients, and it has recently closed a Series A fundraising round to drive the commercialization of its platform.

Keywords: 3D tumor models, precision oncology, drug testing, cancer research, biotech, patient-derived models, evidence-based treatment, 3DTwin technology, oncology, drug discovery